Compliance and patching and atropine amblyopia treatments

• Compliance is a central issue for amblyopia treatments.
• There is a lack of knowledge regarding objective compliance to atropine penalization.
• Non-compliance involves both psychosocial and non-psychosocial factors.

In the past 20 years, there has been a great advancement in knowledge pertaining to compliance with amblyopia treatments. The occlusion dose monitor introduced quantitative monitoring methods in patching, which sparked our initial understanding of the dose–response relationship for patching amblyopia treatment. This review focuses on current compliance knowledge and the impact it has on patching and atropine amblyopia treatment.